Alpha Cognition (ACOG) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
2 Dec, 2025Executive summary
Annual general meeting scheduled for June 19, 2025, to address key governance and compensation matters.
Shareholders will consider financial statements, elect directors, appoint auditors, and vote on a new stock and incentive plan.
Proxy materials are available online, and shareholders are encouraged to vote by proxy if unable to attend.
Voting matters and shareholder proposals
Proposals include setting the board at six directors, electing directors, appointing Manning Elliott LLP as auditor, and approving the 2025 Stock and Incentive Plan.
Shareholders may submit proposals for the next annual meeting by January 5, 2026, for proxy inclusion.
Voting rights: one vote per common or preferred share; no cumulative voting.
Board of directors and corporate governance
Board consists of six members, majority deemed independent under Nasdaq rules.
Committees: Audit (Len Mertz, John Havens, Rob Bakshi), Compensation (Phillip Mertz, Rob Bakshi), Governance and Nomination (Len Mertz, Robert Wills, John Havens).
Board and committees met regularly in 2024; all directors attended at least 75% of meetings.
Board diversity, director qualifications, and annual performance assessments are emphasized.
Code of Business Conduct and Ethics and anti-hedging/insider trading policies in place.
Latest events from Alpha Cognition
- Q2 2026 revenue up 71% QoQ and 268% YoY to $6.0–$6.1M; net loss narrows to $8.8M.ACOG
Q2 2026 - ZUNVEYL posts rapid growth in prescriptions and revenue, targeting a $2B LTC market.ACOG
Corporate presentation - Q1 2026 revenue grew 40% to $3.5M, with strong adoption and a widened net loss on higher costs.ACOG
Q1 2026 - Shareholders will vote on board composition, auditor appointment, and executive compensation.ACOG
Proxy filing - Shareholders to vote on board size, director elections, and auditor appointment at June 2026 AGM.ACOG
Proxy filing - ZUNVEYL's rapid growth and LTC focus drive strong revenue and market expansion.ACOG
Corporate presentation - 2025 revenue hit $10.2M with rapid ZUNVEYL adoption and $66M cash supporting 2027 profitability.ACOG
Q4 2025 - Biopharma seeks up to $250M to fund Alzheimer's drug launch and pipeline, with $75M ATM offering.ACOG
Registration Filing - FDA-approved ZUNVEYL launches in March, targeting LTC Alzheimer's with improved tolerability.ACOG
Investor Update - ZUNVEYL launched in the US, $52.8M raised, and global expansion underway.ACOG
Q4 2024